Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.

A recent study reveals GLP-1 receptor agonists significantly reduce medication use and symptoms in idiopathic intracranial hypertension patients, suggesting a promising management strategy.

Eisai and Biogen seek FDA approval for a convenient, at-home Alzheimer’s treatment option, enhancing patient flexibility and reducing costs.

Semaglutide significantly reduced the risk of heart attack, stroke, and death compared to tirzepatide in patients with obesity and cardiovascular disease.

Research reveals that increased sedentary time significantly impacts neurodegeneration and cognitive decline in older adults, especially those genetically at risk for Alzheimer’s.

The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.

New research reveals that socioeconomic factors, rather than cardiovascular risks, significantly influence the occurrence of nonfocal transient neurologic attacks in older adults.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the use of GLP-1 RAs in neurology.

Neurology News Network. for the week ending August 23, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 22, 2025.

Lea Grinberg, MD, PhD, a neuropathologist at Mayo Clinic Florida, discussed how tau accumulation and orexin neuron loss drive early sleep disturbances in Alzheimer disease and the potential for sleep-based biomarkers.

A recent study highlights that hearing aids significantly lower dementia risk in younger patients with hearing loss, emphasizing the need for early intervention.

The European Medicines Agency has accepted NewAmsterdam Pharma’s application for obicetrapib, an oral CETP inhibitor that lowers LDL-C and shows promise in reducing Alzheimer-related biomarkers.

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonweath University discussed the rationale, results, and future directions of GLP-1 RA therapy as a novel treatment strategy for idiopathic intracranial hypertension.

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University provided hypothetical insights on potential stroke-related avenues for GLP-1 RAs to treat following positive data in idiopathic intracranial hypertension. [WATCH TIME: 4 minutes]

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]

Recently published study links white matter changes to cognitive decline, emphasizing the cingulum and fornix as key biomarkers for memory loss.

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the use of lithium to treat Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 15, 2025.

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the sleep disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.